ABF Tourette's Disorder Post Marketing Surveillance Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA Notification No. 2010-94 dated 27 December 2010).
Condition or disease
This study will be conducted in a prospective, single-arm, multi-center format. As this study is observational in nature, the patient's follow-up is not prescriptive in nature and must be left up to the judgment of the physician (investigator), within the period of observation set forth in the protocol.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Years to 18 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Pediatric patients 6 to 18 years of age with Tourette's Disorder according to the approved product market authorization
Pediatric patients 6 to 18 years of age with Tourette's Disorder
Patients who are prescribed Abilify® treatment as per investigator's medical judgment.
Patients who gave written authorization to use their personal and health data
Patients starting Abilify® treatment after agreement is in place
Patients with known hypersensitivity to Aripiprazole or any excipients of Abilify®
Patients who have been treated with Abilify®
Patients with rare hereditary problems of galactose intolerance, the lapp lactase deficiency, or glucose-galactose malabsorption
Patients with score 0(Not assessed) or 1(Normal, not at all ill) in the TS-CGI-S